Upstream Bio (NASDAQ:UPB) Stock Price Up 7.2% - Here's Why

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report)'s share price rose 7.2% during mid-day trading on Monday . The stock traded as high as $9.48 and last traded at $9.41. Approximately 94,007 shares changed hands during trading, a decline of 71% from the average daily volume of 323,589 shares. The stock had previously closed at $8.78.

Upstream Bio Stock Performance

The company's 50 day moving average is $7.87 and its two-hundred day moving average is $14.45.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Upstream Bio during the fourth quarter worth $25,000. US Bancorp DE bought a new position in Upstream Bio in the fourth quarter worth approximately $27,000. Legal & General Group Plc purchased a new stake in Upstream Bio during the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. acquired a new stake in shares of Upstream Bio in the 4th quarter worth $30,000. Finally, Tower Research Capital LLC TRC acquired a new stake in Upstream Bio in the fourth quarter worth about $47,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.